University Medical Center, Institute for Immunology, Johannes Gutenberg-University, 55131 Mainz, Germany.
J Immunol. 2012 Feb 1;188(3):1091-7. doi: 10.4049/jimmunol.1102045. Epub 2011 Dec 21.
The main molecular mechanism of human regulatory T cell (Treg)-mediated suppression has not been elucidated. We show in this study that cAMP represents a key regulator of human Treg function. Repression of cAMP production by inhibition of adenylate cyclase activity or augmentation of cAMP degradation through ectopic expression of a cAMP-degrading phosphodiesterase greatly reduces the suppressive activity of human Treg in vitro and in a humanized mouse model in vivo. Notably, cAMP repression additionally abrogates the anergic state of human Treg, accompanied by nuclear translocation of NFATc1 and induction of its short isoform NFATc1/αA. Treg expanded under cAMP repression, however, do not convert into effector T cells and regain their anergic state and suppressive activity upon proliferation. Together, these findings reveal the cAMP pathway as an attractive target for clinical intervention with Treg function.
人类调节性 T 细胞 (Treg) 介导的抑制的主要分子机制尚未阐明。本研究表明,cAMP 是人类 Treg 功能的关键调节剂。通过抑制腺苷酸环化酶活性抑制 cAMP 的产生或通过异位表达 cAMP 降解磷酸二酯酶来增强 cAMP 的降解,极大地降低了人类 Treg 在体外和体内人源化小鼠模型中的抑制活性。值得注意的是,cAMP 的抑制还消除了人类 Treg 的无能状态,伴随着 NFATc1 的核易位及其短同工型 NFATc1/αA 的诱导。然而,在 cAMP 抑制下扩增的 Treg 不会转化为效应 T 细胞,并在增殖后恢复其无能状态和抑制活性。总之,这些发现揭示了 cAMP 途径作为一种有吸引力的靶点,可用于干预 Treg 功能。